Koers Pharmagreen Biotech Inc. OTC Markets
Aandelen
PHBI
US00922N1046
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,0289 USD | -.--% | -4,87% | +172,64% |
Omzet 2022 | - | Omzet 2023 | 0 0 | Marktkapitalisatie | 401K 375K |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | - 0 | Nettowinst (verlies) 2023 | - 0 | EV/omzet 2022 | - |
Nettoschuld 2022 | 331K 309K | Nettoschuld 2023 | 372K 348K | EV/omzet 2023 | 257.842.228 x |
K/w-verhouding 2022 |
-4,61
x | K/w-verhouding 2023 |
-0,57
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 87,23% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Wojcik
CEO | Chief Executive Officer | 53 | 09-12-13 |
Terry Kwan
DFI | Director of Finance/CFO | 77 | 22-07-15 |
Ethan Styles
CTO | Chief Tech/Sci/R&D Officer | - | 22-09-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peter Wojcik
CEO | Chief Executive Officer | 53 | 09-12-13 |
Terry Kwan
DFI | Director of Finance/CFO | 77 | 22-07-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+8,57% | 41,34 mld. | |
+49,22% | 41,61 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |
- Beurs
- Aandelen
- Koers PHBI
- Koers PHBI